Summary

2026-07-24 NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo Obicetrapib Monotherapy and Evlarco Obicetrapib Plus Ezetimibe Fixed-Dose Combination NewAmsterdam Pharma Company N.V. Nasdaq: NAMS or NewAmsterdam or the Company, a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease CVD with elevated low-density lipoprotein cholesterol LDL-C, for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group Menarini, today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending marketing authorization for Ubeslo obicetrapib 10 mg monotherapy and Evlarco 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination FDC for patients with primary hypercholesterolemia, both heterozygous familial HeFH and non-familial or mixed dyslipidemia.2026-07-02 Thirty Years To Remember: The Fair Play Menarini Award Shines At The Teatro Del Maggio Musicale Fiorentino For thirty years, the Fair Play Menarini International Award has celebrated champions who have shown that the greatest victory is one built on respect and integrity.

Title

Menarini Group - Quality comes first

Description

The Menarini Group distinguishes itself by quality therapeutics and diagnostics solutions, ethics, innovation, people centricity and sustainability.

Keywords

more, read, play, fair, values, award, innovation, research, stories, group, oncology, diagnostics, patients, company, international, quality, areas

Downstreams

youtube.com, facebook.com

NS Lookup

A 199.232.143.10

Dates

Created 2026-08-12

Updated 2026-08-12

Summarized 2026-08-12